Cargando…
Adaptive servoventilation in clinical practice: beyond SERVE-HF?
Adaptive servoventilation (ASV) has proven effective at suppressing breathing disturbances during sleep, improving quality of life and cardiac surrogate parameters. Since the publication of the SERVE-HF-trial, ASV became restricted. The purpose of this study was to evaluate the clinical relevance of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703354/ https://www.ncbi.nlm.nih.gov/pubmed/29204433 http://dx.doi.org/10.1183/23120541.00078-2017 |
_version_ | 1783281666365587456 |
---|---|
author | Randerath, Winfried Schumann, Katja Treml, Marcel Herkenrath, Simon Castrogiovanni, Alessandra Javaheri, Shahrokh Khayat, Rami |
author_facet | Randerath, Winfried Schumann, Katja Treml, Marcel Herkenrath, Simon Castrogiovanni, Alessandra Javaheri, Shahrokh Khayat, Rami |
author_sort | Randerath, Winfried |
collection | PubMed |
description | Adaptive servoventilation (ASV) has proven effective at suppressing breathing disturbances during sleep, improving quality of life and cardiac surrogate parameters. Since the publication of the SERVE-HF-trial, ASV became restricted. The purpose of this study was to evaluate the clinical relevance of the SERVE-HF inclusion criteria in real life and estimate the portion of patients with these criteria with or without risk factors who are undergoing ASV treatment. We performed a retrospective study of all patients who were treated with ASV in a university-affiliated sleep laboratory. We reviewed the history of cardiovascular diseases, echocardiographic measurements of left ventricular ejection fraction (LVEF) and polysomnography. From 1998 to 2015, 293 patients received ASV, of which 255 (87.0%) had cardiovascular diseases and 118 (40.3%) had HF. Among those with HF, the LVEF was ≤45% in 47 patients (16.0%). Only 12 patients (4.1%) had LVEF <30%. The SERVE-HF inclusion criteria were present in 28 (9.6%) ASV recipients. Of these patients, 3 died within 30–58 months of therapy, all with systolic HF and a LVEF <30%. In this study, only a small minority of ASV patients fell in the risk group. The number of fatalities did not exceed the expected mortality in optimally treated systolic HF patients. |
format | Online Article Text |
id | pubmed-5703354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-57033542017-12-04 Adaptive servoventilation in clinical practice: beyond SERVE-HF? Randerath, Winfried Schumann, Katja Treml, Marcel Herkenrath, Simon Castrogiovanni, Alessandra Javaheri, Shahrokh Khayat, Rami ERJ Open Res Original Articles Adaptive servoventilation (ASV) has proven effective at suppressing breathing disturbances during sleep, improving quality of life and cardiac surrogate parameters. Since the publication of the SERVE-HF-trial, ASV became restricted. The purpose of this study was to evaluate the clinical relevance of the SERVE-HF inclusion criteria in real life and estimate the portion of patients with these criteria with or without risk factors who are undergoing ASV treatment. We performed a retrospective study of all patients who were treated with ASV in a university-affiliated sleep laboratory. We reviewed the history of cardiovascular diseases, echocardiographic measurements of left ventricular ejection fraction (LVEF) and polysomnography. From 1998 to 2015, 293 patients received ASV, of which 255 (87.0%) had cardiovascular diseases and 118 (40.3%) had HF. Among those with HF, the LVEF was ≤45% in 47 patients (16.0%). Only 12 patients (4.1%) had LVEF <30%. The SERVE-HF inclusion criteria were present in 28 (9.6%) ASV recipients. Of these patients, 3 died within 30–58 months of therapy, all with systolic HF and a LVEF <30%. In this study, only a small minority of ASV patients fell in the risk group. The number of fatalities did not exceed the expected mortality in optimally treated systolic HF patients. European Respiratory Society 2017-10-23 /pmc/articles/PMC5703354/ /pubmed/29204433 http://dx.doi.org/10.1183/23120541.00078-2017 Text en Copyright ©ERS 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Original Articles Randerath, Winfried Schumann, Katja Treml, Marcel Herkenrath, Simon Castrogiovanni, Alessandra Javaheri, Shahrokh Khayat, Rami Adaptive servoventilation in clinical practice: beyond SERVE-HF? |
title | Adaptive servoventilation in clinical practice: beyond SERVE-HF? |
title_full | Adaptive servoventilation in clinical practice: beyond SERVE-HF? |
title_fullStr | Adaptive servoventilation in clinical practice: beyond SERVE-HF? |
title_full_unstemmed | Adaptive servoventilation in clinical practice: beyond SERVE-HF? |
title_short | Adaptive servoventilation in clinical practice: beyond SERVE-HF? |
title_sort | adaptive servoventilation in clinical practice: beyond serve-hf? |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703354/ https://www.ncbi.nlm.nih.gov/pubmed/29204433 http://dx.doi.org/10.1183/23120541.00078-2017 |
work_keys_str_mv | AT randerathwinfried adaptiveservoventilationinclinicalpracticebeyondservehf AT schumannkatja adaptiveservoventilationinclinicalpracticebeyondservehf AT tremlmarcel adaptiveservoventilationinclinicalpracticebeyondservehf AT herkenrathsimon adaptiveservoventilationinclinicalpracticebeyondservehf AT castrogiovannialessandra adaptiveservoventilationinclinicalpracticebeyondservehf AT javaherishahrokh adaptiveservoventilationinclinicalpracticebeyondservehf AT khayatrami adaptiveservoventilationinclinicalpracticebeyondservehf |